According to a recent LinkedIn post from Neuromod Devices Ltd, the Atlanta VA Health Care System has begun using the company’s Lenire technology to treat tinnitus in Veterans as of April 2, 2026. The post highlights that an Army Veteran, identified as Profit Lucy, is among the first patients at the facility to receive the treatment and is quoted describing anticipated quality-of-life benefits.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post notes that tinnitus affects 3.2 million U.S. Veterans and is described as the number one service-connected disability in the latest Annual Benefits Report. This context suggests that adoption of Lenire within the VA system, even at an early stage, may represent access to a large addressable patient population and potential pathway for broader deployment across federal health facilities.
For investors, the post implies early clinical integration of Neuromod’s technology into a major government-funded care network, which could support recurring device and therapy revenues if utilization scales. Visibility via the Veterans Affairs website and association with a high-need indication may also strengthen Neuromod’s positioning in the tinnitus treatment market and enhance its profile with both payers and clinicians.